HER2-positive Breast Cancer, Metastatic Breast Cancer
Conditions
Brief summary
To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.
Interventions
DRUGTrastuzumab
Dual anti-HER2 therapy
Sponsors
Shandong Cancer Hospital and Institute
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* woman, age \> 18 years old * Diagnosed with HER2 +Metastatic Breast Cancer * Pyrotinib Combined With Trastuzumab And Chemotherapy for at least one cycle, starting from 2020.11.01-2021.10.31 * Available medical history
Exclusion criteria
* Incomplete medical history
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival(PFS) | 1 year | The time from starting pyrotinib until disease progression or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival(OS) | 1 year | The time from starting pyrotinib until death, regardless of cause. |
| Objective Response Rate(ORR) | 1 year | The proportion of patients with complete response (CR) or partial response (PR) |
| Safety | 1 year | Number of participants with adverse events which were collected at 6 and 18 months after the start of pyrotinib |
Contacts
Primary ContactZhiyong Yu, PhD
Backup ContactChao Li, MD
Outcome results
None listed